No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.
No article has been written about this topic yet.
Be the first one to add some text.
Loading AI-assisted edit mode...
Timeline
November 20, 2020
Glycostem Therapeutics announces the opening of a phase I/IIa trial for its lead product oNKord® for the treatment of AML patients.
2007
Glycostem was founded.
People
Name
Role
LinkedIn
Hareth Nahi
CMO
Jan Spanholtz
CSO
Troels Jordansen
CEO
Volker Huppert
COO
Further reading
Title
Author
Link
Type
Date
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services
News
Title
Author
Date
Publisher
Description
Glycostem Therapeutics
December 15, 2020
www.prnewswire.com:443
/PRNewswire/ -- Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic off-the-shelf Natural Killer (NK)...
Glycostem Therapeutics
November 20, 2020
www.prnewswire.com:443
/PRNewswire/ -- Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic off-the-shelf Natural Killer (NK)...
References
Is a
Company attributes
Location
Date incorporated
2007
Founded date
2007
